Treating claudication and rest pain due to chronic total occlusion of the SFA

Severe peripheral arterial disease (PAD)

Challenge

  •  65-year-old woman presented with severe peripheral arterial disease, claudication and rest pain of left lower extremity
  • Angiography revealed total occlusion of the left superficial femoral artery (SFA)

Images courtesy of James Otto, M.D. Used with permission.

angiogram

Procedure

  • Obtained percutaneous access into the right femoral artery with ultrasound guidance. Then performed an angiogram of the left lower extremity.
  • Crossed SFA chronic total occlusion (CTO) with 035 TERUMO® RADIFOCUS® GLIDEWIRE® ADVANTAGE and 035 TERUMO® NAVICROSS® Support Catheter 
  • Atherectomy completed with CARDIOVASCULAR SYSTEMS DIAMONDBACK 360® Peripheral Orbital Atherectomy System 2.0 Solid Crown  
  • Followed by angioplasty with a 5 mm percutaneous transluminal angioplasty (PTA) balloon 
  • Deployed two 6 mm x 15 cm GORE® VIABAHN® Devices in the SFA and post-dilated with 6 mm PTA balloon

Image courtesy of James Otto, M.D. Used with permission.

Completion angiogram

Result

  • Completion angiogram showed excellent flow of the left lower extremity. Immediately post-op, complete resolution of left sided severe claudication.
  • At follow-up office visit 2.5 weeks post-op, the patient presented with complete resolution of claudication and rest pain. Patient had palpable tibial pulses bilaterally

Image courtesy of James Otto, M.D. Used with permission.

Case takeaways

  • As demonstrated in this case, the GORE® VIABAHN® Endoprosthesis offers excellent patency in the treatment of long SFA total occlusions and should be considered first-line treatment for complex SFA disease

The GORE® VIABAHN® Endoprosthesis has demonstrated durability and long-term patency in treatment of complex SFA disease with 97% three-year secondary patency (27 cm average lesion length, 93% CTOs)1
  1. GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface [Instructions for Use]. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2021. MD174703.

This content is for informational purposes only, is not advice or a guarantee of outcome. It is not a substitute for professional medical advice, diagnosis or treatment. Individual results and/or treatment may vary based upon the circumstances, the patient’s specific situation, and the healthcare provider’s medical judgment.

Visit our clinical uses page

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.